NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

iclight,

Thanks for reposting that once again about ASCO! It was a brilliant presentation in the Industry Expert Theatre! They had a spectacular booth too!

I also agree that combo therapy is the centerpiece of DCVax-L in terms of enhanced efficacy and a broader range of indications beyond GBM!

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171909324

The interim PD1 combo data are brilliant, and the trial is significant for a number of reasons relating to FDA guidelines and NIH peer-reviewed grant funding.



https://clinicaltrials.gov/ct2/show/NCT04201873

https://www.fda.gov/media/120721/download

In the combo trial, patients who receive DCVax-L + placebo are being compared to patients who receive DCVax-L + pembrolizumab.

The control arm is receiving DCVax-L. While DCVax-L is not the current SOC, it is highly significant and notable that DCVax-L is being permitted to fill the role of SOC as the best available therapy within this combo study for rGBM. The combo trial also follows the P3 in sequence which in itself validates the findings of the P3 study—the placebo group in the PD1 study would not be receiving DCVax-L today if the preceding P3 trial had not proven its efficacy.





https://brownneurosurgery.com/breakthrough-brain-cancer-vaccine/





Don’t miss the next presentation in September 2023!







https://www.cns.org/annualmeeting